Mylan Launches First Trastuzumab Biosimilar in India

Mylan, a generic and specialty pharmaceutical company, reported that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz, is a biosimilar to Roche's Herceptin. Hertraz is indicated for the treatment of HER2-positive metastatic breast cancer and is available in 440 mg and 150 mg.  Hertraz was approved by the Drug Controller General of India.

Trastuzumab is one of the five biologic products Mylan is developing in partnership with Biocon for the global marketplace. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the US, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries. In addition, Mylan has co-exclusive commercialization rights with Biocon for the product in India.